Depression – Is a mood disorder that causes a constant feeling of sadness and no interest in day to day routines. It affects how you feel, behave and think.
Depression is usually treated with monoamine-based antidepressants such as selective serotonin reuptake inhibitors (SSRI’s) which are known as Citalopram (Celexa), Escitalopram (Lexapro), Fluoxetine (Prozac), Paroxetine (Paxil, Pexeva), Sertraline (Zoloft) and Vilazodone (Viibryd) and about 1/3 of depressive patients are not responsive to these anti-depressants.
Side effects from SSRI’s consist of drowsiness, nausea, dry mouth, insomnia, diarrhea, nervousness, agitation or restlessness, dizziness, sexual problems, such as reduced sexual desire or difficulty reaching orgasm or inability to maintain an erection (erectile dysfunction), headache and blurred vision.
Memory and Learning – In Asia, they have been treating depression with Traditional Chinese Medicine, specifically a Chinese herb called XingPiJieYu (XPJY) for many years and in a recent 21-day study on rats, studies are showing XingPiJieYu is improving memory and learning by improving the signaling pathway in the hippocampus. The hippocampus is a small organ located within the brain’s medial temporal lobe and forms an important part of the limbic system, the region that regulates emotions. The hippocampus is involved in the storage of long-term memory, which includes all past knowledge and experiences.
Chronic Unpredictable Stress (CUS) – According to the National Center of Biotechnology Information (NCBI), There were past studies that showed XPJY improved behavior and depression in CUS in rats, which they say, is as good as sertraline.
The NCBI conclusion read as follows “XPJY has a regulatory effect on depressive behavior in the sucrose preference and open field exploration, and learning and memory in Morris water maze, and the expression of cAMP, PKA, CREB and BDNF in the hippocampus of model rats. The effect is probably achieved mainly by activating cAMP-PKA-CREB-BDNF signaling pathway. This study provides experimental evidence for the clinical application of XPJY in the treatment of depression and related learning and memory impairment.